Patents Issued in August 13, 2020
  • Publication number: 20200253905
    Abstract: A first aspect of the invention relates to leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a migraine, or one or more symptoms associated therewith. A second aspect of the invention relates to a method of treating or preventing a migraine, or one or more symptoms associated therewith, in a subject, said method comprising administering to the subject a therapeutically or prophylactically effective amount of leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 25, 2018
    Publication date: August 13, 2020
    Inventors: MICHAEL STRUPP, Mallory FACTOR
  • Publication number: 20200253906
    Abstract: Composition for promoting mitochondrial biogenesis and improving mitochondrial function in a subject, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid, malic acid.
    Type: Application
    Filed: July 20, 2018
    Publication date: August 13, 2020
    Inventor: Paolo Luca Maria GIORGETTI
  • Publication number: 20200253907
    Abstract: Disclosed herein are methods and compounds for treating neurodegenerative diseases and disorders with one or more neurodegenerative therapeutics and/or amino acid derivatives or analogs.
    Type: Application
    Filed: August 20, 2018
    Publication date: August 13, 2020
    Inventors: Jing Huang, Min Chai, Brett Eugene Lomenick, Meisheng Jiang, Randall M. Chin
  • Publication number: 20200253908
    Abstract: The present invention encompasses an amino acid composition for stimulating muscle protein synthesis. Further, the present disclosure relates generally to the use of an anabolic amino acid composition for the stimulation of muscle protein synthesis. In particular, disclosed are compositions and methods of using the same for the prevention and/or treatment of a loss of any one of muscle mass, muscle strength, muscle function, and physical function, or any combination thereof, in a mammal, especially an adult mammal. Also provided are kits comprising a composition for the stimulation of muscle protein synthesis and, in certain embodiments, instructions for administration.
    Type: Application
    Filed: November 2, 2018
    Publication date: August 13, 2020
    Inventors: Robert R. Wolfe, Arny Ferrando
  • Publication number: 20200253909
    Abstract: Ketogenic compositions include a racemic mixture of R- and S-beta-hydroxybutyric acids and a racemic mixture of R- and S-beta-hydroxybutyrate salts. The compositions contain the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved and yet contain an equivalent amount of the S-enantiomer to provide alternative benefits. The R- and S-beta-hydroxybutyric acids are more rapidly absorbed and utilized by the body than salts or esters, enhance taste, and reduce the need to include citric acid or other edible acids. The R- and S-beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. The ketogenic composition may contain a dietetically or pharmaceutically acceptable carrier and a racemic mixture of R- and S-beta-hydroxybutyrate salts and acids. The composition contains less than 100% by molar equivalents of total R,S-beta-hydroxybutyrate salts and more than 0% by molar equivalents of R,S-beta-hydroxybutyric acids.
    Type: Application
    Filed: February 6, 2020
    Publication date: August 13, 2020
    Inventor: Gary Millet
  • Publication number: 20200253910
    Abstract: The invention provides methods for reducing the percentage of body fat, increasing the level of adiponectin, and/or treating or reducing the risk of cardiovascular disease (CVD) and coronary heart disease (CHD). Such methods include administering to an animal or human sufficient levels of a compound comprising a tri blend of HPMC (K15, K100, and K200) and myristic fatty acid.
    Type: Application
    Filed: April 27, 2020
    Publication date: August 13, 2020
    Applicant: First Fruits Business Ministry, LLC
    Inventors: Roger J. Catarino, William D. Kuhne
  • Publication number: 20200253911
    Abstract: Methods of treating the side effects of a toxic medical therapy using nitrated lipids are disclosed herein. In particular, the methods comprise the use of nitrated fatty acids or esters thereof to treat side effects, including organ system damage, caused by chemotherapy, radiotherapy, and the administration of other toxic agents.
    Type: Application
    Filed: January 27, 2020
    Publication date: August 13, 2020
    Inventor: Tianxin YANG
  • Publication number: 20200253912
    Abstract: The present disclosure provides, in part, modulators of prostate-specific G-protein receptor (OR51E2/PSGR) and methods of treating, preventing, and diagnosing prostate cancer using the same.
    Type: Application
    Filed: February 3, 2020
    Publication date: August 13, 2020
    Inventors: Tatjana Abaffy, Hiro Matsunami
  • Publication number: 20200253913
    Abstract: Provided here are therapeutically effective pharmaceutical compositions containing one or more TREX2 inhibitors, and more specifically methods of administering TREX2 inhibitors to increase the effectiveness of a chemotherapeutic agent. Also provided here are methods of identifying agents that inhibit the exonuclease activity of TREX2.
    Type: Application
    Filed: October 16, 2018
    Publication date: August 13, 2020
    Inventors: Edward Paul HASTY, Dmitri Nickolaevich IVANOV
  • Publication number: 20200253914
    Abstract: The present invention is directed to a novel combination of excipients with an active ingredient, such as Benzoyl Peroxide based (BPO) which is subject to degradation. In one embodiment the invention is a topical pharmaceutical or cosmetic cleanser composition comprising benzoyl peroxide present in an amount from about 2.0 to about 20% w/w; water, at least one anionic surfactant which is a alkylpolyglucoside (AG) derivative surfactant; at least one humectant, a thickening agent, and optionally at least one dermatologically acceptable excipient.
    Type: Application
    Filed: November 8, 2016
    Publication date: August 13, 2020
    Inventors: Alireza SHALVIRI, Martyn J. CLARKE
  • Publication number: 20200253915
    Abstract: The present application relates to use of a nitric oxide releasing agent in the preparation of a medicament for preventing or treating diseases or disorders associated with administration of a VEGFR inhibitor and/or VEGF inhibitor. The present application further provides a method for preventing or treating diseases or disorders associated with administration of a VEGFR inhibitor and/or VEGF inhibitor in a subject. The method comprise administering, to a subject in need, a prophylactically or therapeutically effective amount of the nitric oxide releasing agent.
    Type: Application
    Filed: April 22, 2020
    Publication date: August 13, 2020
    Inventors: Shiyi Zhang, Zhaoyu Wu, Chao Liu, Linan Yang, Leying Chen, Jie Luo
  • Publication number: 20200253916
    Abstract: The disclosure relates to compositions and methods of treating cancer in a subject. The method comprises administering to a patient in need of treatment an effective amount of supercritical CO2 neem extract.
    Type: Application
    Filed: August 30, 2019
    Publication date: August 13, 2020
    Inventor: Michael Wargovich
  • Publication number: 20200253917
    Abstract: The present disclosure relates to pharmaceutical compositions containing electron transport chain (ETC) inhibitors, which are capable of promoting hair growth. The disclosure further relates to methods of promoting hair growth or treating conditions or disorders affecting hair growth, such as baldness or alopecia.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 13, 2020
    Inventors: William E. Lowry, Heather R. Christofk, Matilde Miranda, Aimee Flores
  • Publication number: 20200253918
    Abstract: A cannabis-based flavonoid pharmaceutical composition including any one or more selected from among the group of Cannflavin A, Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside and their derivatives selected from among the group of Geraldol, Rhamnetin, Isorhamnetin, Rhamnazin, or their synthases, for the prevention and treatment of certain cancers that can be treated by therapeutically targeting oncogenic factors including kinases, sirtuins, bromodomains, matrix metalloproteinases and histone acetylases. Some of the cancers that can be treated by use of cannabis flavonoids based on the inhibition of these therapeutic targets include but are not limited to brain, breast, colon, renal liver, lung, pancreatic, pigmented villonodular synovitis, prostate, leukemia, melanomam, tenosynovial giant cell tumor, as well as any other cancers that overexpress the oncogenic factors inhibited, by the cannabis flavonoids or their derivatives herein identified.
    Type: Application
    Filed: November 27, 2019
    Publication date: August 13, 2020
    Inventors: Henry Lowe, Ngeh J. Toyang
  • Publication number: 20200253919
    Abstract: A product for treating conditions and/or symptoms associated with women health is described, which product comprises at least one cannabinoid in a specific amount, a primary terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene, carrier, optionally at least three secondary terpenes, and optionally at least one phytoestrogen; wherein said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight/weight ratio in said product is about 0.1 to about 1.0. Also described is the product wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and the terpenes to cannabinoids weight/weight ratio in said compositions is about 0.05 to about 1.0, forming a terpene-enriched product.
    Type: Application
    Filed: December 25, 2019
    Publication date: August 13, 2020
    Inventors: Noa Raz, Aharon M. Eyal
  • Publication number: 20200253920
    Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).
    Type: Application
    Filed: January 8, 2020
    Publication date: August 13, 2020
    Applicants: Auransa Inc., SCT II LLC
    Inventors: Christopher G. ARMSTRONG, Kevin J. KIM, Lisa Maria Lucia PHAM, Eunhye PARK, Zhong ZHONG, Guanyi HUANG, Joseph C. WU, Sidney Paul ELMER, Viwat VISUTHIKRAISEE, Eithon Michael G. CADAG, Thomas Bernard FREEMAN, Pek Yee LUM
  • Publication number: 20200253921
    Abstract: The disclosure is directed to formulations comprising cannabinoids. More particularly, the cannabinoid formulations can be designed to align with an individual's genotype based on a defined list of polymorphisms.
    Type: Application
    Filed: October 30, 2018
    Publication date: August 13, 2020
    Inventors: Len May, Eric Kaufman
  • Publication number: 20200253922
    Abstract: The present invention is directed to the administration of a cannabinoid aerosol formulation using a soft mist inhaler (SMI) with reduced cannabinoid-related irritation and/or coughing. Described is an aerosol formulation comprising a cannabinoid in an ethanol solution and further comprising saccharin or a salt thereof, an aerosol formulation comprising a cannabinoid in a solution comprising ethanol and saline, and methods for the use thereof.
    Type: Application
    Filed: February 12, 2020
    Publication date: August 13, 2020
    Inventors: Nicholas J. Boylan, Scott S. Finnance, Tuna Yucel, Stephen E. Zale
  • Publication number: 20200253923
    Abstract: Provided are homogeneous cannabis plant material compositions comprising tetrahydrocannabinol (THC) and cannabidiol (CBD) at specified concentrations, wherein the plant material is in the form of comminuted particles; wherein at least 70 wt % of the comminuted cannabis plant material is of a size greater than 0.3 and less than 4.2 millimeters; and wherein the composition comprises at least 1 wt % and less than 20 wt % moisture. Further provided are products comprising the compositions and methods of preparation thereof.
    Type: Application
    Filed: April 30, 2020
    Publication date: August 13, 2020
    Inventor: Aharon EYAL
  • Publication number: 20200253924
    Abstract: This disclosures relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.
    Type: Application
    Filed: April 28, 2020
    Publication date: August 13, 2020
    Inventor: Kurt Aron Levy
  • Publication number: 20200253925
    Abstract: The present invention concerns a pharmaceutical composition comprising a compound of Formula I for use in the treatment and/or prevention of microbial infections. Furthermore, the present invention concerns a method for prevention and/or reduction of biofilm formation.
    Type: Application
    Filed: October 5, 2018
    Publication date: August 13, 2020
    Applicant: GEDEA BIOTECH AB
    Inventors: Ulf ELLERVIK, Olov STERNER, Helena STREVENS, Sophie MANNER
  • Publication number: 20200253926
    Abstract: Methods of treatment include administering effective amounts of a nitrogen oxide (NO) donor (such as nicorandil) and a hydrogen sulfide (H2S) releasing agent (such as zofenopril) to a subject in need thereof. In various embodiments, the H2S releasing agent is administered in an amount that is effective to enhance the therapeutic efficacy of the NO donor. Coformulations of the H2S releasing agent and the NO donor are provided that are suitable for treating a number of conditions. In various embodiments, treatments for conditions such as chronic kidney disease, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, familial dilated cardiomyopathy and/or idiopathic dilated cardiomyopathy are provided.
    Type: Application
    Filed: February 11, 2020
    Publication date: August 13, 2020
    Inventors: Neil M. Cowen, Khaled Yamout
  • Publication number: 20200253927
    Abstract: Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations of venetoclax and indolinone derivatives are provided.
    Type: Application
    Filed: April 13, 2020
    Publication date: August 13, 2020
    Inventors: Brian Lannutti, Katayoun Jessen, James Bradley Breitmeyer
  • Publication number: 20200253928
    Abstract: Provided is a composition for reducing serum uric acid level, which contains glycine and tryptophan. The serum uric acid level in a subject can be decreased when the subject intakes the composition.
    Type: Application
    Filed: August 1, 2018
    Publication date: August 13, 2020
    Applicant: ASAHI GROUP HOLDINGS, LTD.
    Inventor: Shunji OSHIMA
  • Publication number: 20200253929
    Abstract: The present invention discloses pseurotins and azaspirofurans and their use in the treatment and prevention in epilepsy and other seizures. The present invention further discloses methods to screen pseurotin- and azaspirofuran-like molecules as pharmaceutically active compounds.
    Type: Application
    Filed: August 28, 2018
    Publication date: August 13, 2020
    Inventors: Daniëlle Copmans, Peter De Witte, Rainer Ebel, Marcel Jaspars, Annelii Ny, Mostafa Rateb, Alan Smith, Jioji Tabudravu
  • Publication number: 20200253930
    Abstract: The present invention relates to 3-(5-fluoroindolyl)-4-arylmaleimide compounds and pharmaceutical compositions containing them. The compounds of the present invention are protein kinases (GSK-3beta, VEGFR-2 and FLT-3) with antineoplastic activity. They can therefore be used for the treatment or prevention of tumors, in particular solid tumors.
    Type: Application
    Filed: December 28, 2016
    Publication date: August 13, 2020
    Inventors: Markus Möhler, Annett Maderer, Gerd Dannhardt, Christopher Ganser, Eva Lauermann, René Mönnikes
  • Publication number: 20200253931
    Abstract: The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
    Type: Application
    Filed: April 6, 2020
    Publication date: August 13, 2020
    Inventors: William H. Pitlick, Alan R. Meyer, Mina Sooch, Konstantinos Charizanis, Bernhard Hoffmann
  • Publication number: 20200253932
    Abstract: Transforming growth factor ? (TGF?) transcriptional responses are involved in the pathogenesis of aortic aneurism syndromes. Compositions that inhibit histone acetyltransferase activity normalize gene expression in the aorta, preserved aortic wall architecture and abrogated aneurism progression. Methods include the use of these compositions to epigenetically regulate abnormal expression and/or activity of TGF? genes.
    Type: Application
    Filed: August 31, 2018
    Publication date: August 13, 2020
    Inventors: Harry C. Dietz, Benjamin Edward Kang
  • Publication number: 20200253933
    Abstract: A method of treating a patient comprises orally administering a solid oral dosage form comprising a core comprising a non-ionic polymer matrix, a first amount of ondansetron dispersed within the matrix, and a salt dispersed within the matrix, wherein the first amount of ondansetron ranges from about 9 mg to about 28 mg; a first seal coat surrounding the core, wherein the first seal coat is comprised of a non-ionic polymer matrix; and an immediate release drug layer surrounding the first seal coat and comprising a non-ionic polymer and a second amount of ondansetron dispersed therein, wherein the second amount of ondansetron ranges from about 3 mg to about 8 mg, wherein release of ondansetron from the solid oral dosage form provides exposure to ondansetron for a minimum period of 16 hours so as to result in a reduction in frequency of vomiting, nausea, diarrhea, or a combination thereof.
    Type: Application
    Filed: April 29, 2020
    Publication date: August 13, 2020
    Inventors: Reza Fathi, Gilead Raday, Guy Goldberg
  • Publication number: 20200253934
    Abstract: The present provides compounds and methods for preventing and/or treating epilepsy and/or neurodegenerative disorders. More particularly, the invention provides inhibitors of PDE6? for use in the prevention and/or treatment of neurodegenerative disorders and/or epilepsy.
    Type: Application
    Filed: May 11, 2018
    Publication date: August 13, 2020
    Inventors: Johan Gerard Griffioen, Katrien Princen, Tom François L. Van Dooren, Koen De Witte
  • Publication number: 20200253935
    Abstract: The present invention is directed to methods of treating, preventing, and/or ameliorating systemic sclerosis, by administration of a therapeutically effective amount of ifetroban or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 30, 2020
    Publication date: August 13, 2020
    Inventors: Leo Pavliv, James West, Ines Macias-Perez, Erica Carrier
  • Publication number: 20200253936
    Abstract: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-?) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-?) inhibitors, and to methods for regulating angiogenesis.
    Type: Application
    Filed: September 20, 2019
    Publication date: August 13, 2020
    Inventors: Jeffrey Lyle Gray, Kande K.D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier
  • Publication number: 20200253937
    Abstract: The invention provides deuterium-enriched thiazolidine-2,4-dione compounds (i.e., deuterium-enriched glitazone compounds), enantiopure forms of deuterium-enriched glitazone compounds, pharmaceutical compositions, and methods of treating medical disorders, such as a metabolic disorder, neurological disorder, cancer, or other disorder using deuterium-enriched glitazone compounds, which are preferably in enantiopure form.
    Type: Application
    Filed: August 15, 2019
    Publication date: August 13, 2020
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • Publication number: 20200253938
    Abstract: A once-a-day controlled release oral dosage form of methazolamide is provided. The dosage form comprises a therapeutically effective amount of methazolamide and a high molecular weight binder. The dosage is configured for once-daily administration to a subject in need thereof, and releases methazolamide over a period of about twenty-four hours.
    Type: Application
    Filed: November 14, 2019
    Publication date: August 13, 2020
    Inventor: Nabil Rizk
  • Publication number: 20200253939
    Abstract: This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.
    Type: Application
    Filed: May 1, 2020
    Publication date: August 13, 2020
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang
  • Publication number: 20200253940
    Abstract: A method of use for Cpd 1 as an inhibitor of dihydroorotate dehydrogenase (DHODH) function in treating or ameliorating a hematological cancer in a subject in need thereof comprising, administering an effective amount of Cpd 1 to the subject, having structure (I); or a form or pharmaceutical composition thereof.
    Type: Application
    Filed: August 1, 2018
    Publication date: August 13, 2020
    Inventors: Liangxian Cao, Maria Weetall
  • Publication number: 20200253941
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Application
    Filed: February 7, 2020
    Publication date: August 13, 2020
    Applicant: XSPRAY MICROPARTICLES AB
    Inventors: Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
  • Publication number: 20200253942
    Abstract: A pathological mechanism in FOP patients is further revealed, and development of a novel therapeutic drug, therapeutic method, diagnostic method, etc. utilizing an obtained finding is provided. The inventors have found a novel finding that in FOP, ectopic ossification, which occurs by an inflammation due to an injury, etc., is mediated by PAR1 to occur. From this finding, the inventors completed the present invention relating to a drug, etc. characterized by suppressing ectopic ossification in FOP by inhibiting PAR1.
    Type: Application
    Filed: November 17, 2016
    Publication date: August 13, 2020
    Inventors: Takumi ERA, Takayuki Kiboku
  • Publication number: 20200253943
    Abstract: This invention relates to the finding that Piperlongumine compounds, such as Piperlongumine and analogues, derivatives and prodrugs thereof, are reversible, allosteric antagonists of transient receptor potential vanilloid 2 channel (TRPV2).
    Type: Application
    Filed: September 14, 2018
    Publication date: August 13, 2020
    Inventors: Goncalo Bernardes, Tiago Rodrigues, João Conde, Charlotte Baker
  • Publication number: 20200253944
    Abstract: The invention provides topical pharmaceutical gel compositions for the treatment of chronic skin damage, specifically for damage caused by neuropathic ulcers and preferably for the treatment of diabetic foot, and in the treatment of vascular ulcers wherein said compositions comprise a combination of Modified Diallyl Disulfide Oxide (M-DDO) (as an antiseptic/antibiotic agent) and 5-methyl-1-phenyl-2(1H)-pyridone. Furthermore, the invention describes methods of treatment, applications and/or pharmaceutical uses in the preparation of medicaments for eliminating, reducing or preventing chronic skin lesions and the damages caused by neuropathic ulcers and particularly in the treatment of diabetic foot and in the treatment of vascular ulcers.
    Type: Application
    Filed: August 10, 2018
    Publication date: August 13, 2020
    Inventors: José Agustín Rogelio MAGAÑA CASTRO, Juan Socorro ARMENDÁRIZ BORUNDA
  • Publication number: 20200253945
    Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.
    Type: Application
    Filed: October 25, 2018
    Publication date: August 13, 2020
    Inventors: Bernard Charles SHERMAN, Michael SPINO
  • Publication number: 20200253946
    Abstract: The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the core is free of a surfactant. The prior art discloses restrictive formulation techniques and suggests higher amounts of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.
    Type: Application
    Filed: December 13, 2019
    Publication date: August 13, 2020
    Applicant: Jubilant Generics Limited
    Inventors: Kamal Surendrakumar Mehta, Saurabh Srivastava, Dinesh Kumar, Amit Kumar Jha, Subash Chandra Mohanta, Sunil Kumar Panda, Ganesh Vinayak Gat
  • Publication number: 20200253947
    Abstract: Provided herein are formulations for treating affective mood disorders. The formulations comprise one or more than one CB receptor agonist and one or more than one serine hydrolase enzyme inhibitor.
    Type: Application
    Filed: February 7, 2019
    Publication date: August 13, 2020
    Applicant: Medipure Pharmaceuticals Inc.
    Inventors: Rashmi Tiwari-Pandey, Rakshit Devappa Kodekalra, Nihar R. Pandey
  • Publication number: 20200253948
    Abstract: Provided herein are formulations for treating affective mood disorders. The formulations comprise one or more than one CB receptor agonist and one or more than one serine hydrolase enzyme inhibitor.
    Type: Application
    Filed: October 31, 2019
    Publication date: August 13, 2020
    Applicant: Medipure Pharmaceuticals Inc.
    Inventors: Rashmi TIWARI-PANDEY, Rakshit Devappa KODEKALRA, Nihar R. PANDEY
  • Publication number: 20200253949
    Abstract: Compounds of the formula I in which X, Q, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.
    Type: Application
    Filed: March 27, 2017
    Publication date: August 13, 2020
    Applicant: Merck Patent GmbH
    Inventor: Hans-Peter BUCHSTALLER
  • Publication number: 20200253950
    Abstract: The present invention relates to pharmaceutical compositions containing one or more compounds of formula 1 wherein R1 is H, C1-6-alkyl, C0-4-alkyl-C3-6-cycloalkyl, C1-6-haloalkyl; R2 is H, C1-6-alkyl; X is an anion selected from the group consisting of chloride or ½ dibenzoyltartrate; j is 1 or 2; and processes for the preparation thereof, and their use to treat diseases connected with the CCR3 receptor.
    Type: Application
    Filed: April 29, 2020
    Publication date: August 13, 2020
    Inventors: Alfred Fetscher, Jochen Matthias Scher
  • Publication number: 20200253951
    Abstract: One of the major issues against the use of muscarinic antagonists or dopamine agonist eyedrops for the controlling of eye growth and prevention of myopia is the unacceptable rate of iatrogenic conjunctivitis or dermatitis. This invention relates to the association of those active principles with an antiallergic component. In alternative the ophthalmic use of a molecule that simultaneously has an antimuscarinic and/or dopaminergic action along with an antihistaminic function.
    Type: Application
    Filed: February 17, 2017
    Publication date: August 13, 2020
    Inventor: Enzo Maria D'Ambrosio
  • Publication number: 20200253952
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: April 27, 2020
    Publication date: August 13, 2020
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Charles Arthur, Margaret Bradbury, Thomas George Gant, Manouchehr Shahbaz
  • Publication number: 20200253953
    Abstract: The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.
    Type: Application
    Filed: December 5, 2019
    Publication date: August 13, 2020
    Inventor: Karel Marie Joseph Brands
  • Publication number: 20200253954
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: September 20, 2019
    Publication date: August 13, 2020
    Applicant: AbbVie Inc.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers